Shares of OptiNose Inc (NASDAQ:OPTN) have been given an average rating of “Buy” by the six research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $27.50.

A number of equities analysts recently commented on OPTN shares. Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 target price on shares of OptiNose in a research report on Monday, February 4th. ValuEngine cut shares of OptiNose from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research upgraded shares of OptiNose from a “sell” rating to a “hold” rating in a research report on Tuesday, January 15th. Finally, Royal Bank of Canada decreased their target price on shares of OptiNose to $25.00 and set an “outperform” rating on the stock in a research report on Thursday, March 7th.

Several hedge funds have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of OptiNose in the fourth quarter valued at about $45,000. Teachers Advisors LLC increased its position in shares of OptiNose by 31.9% in the third quarter. Teachers Advisors LLC now owns 31,601 shares of the company’s stock valued at $393,000 after acquiring an additional 7,641 shares during the period. Rhumbline Advisers increased its position in shares of OptiNose by 58.5% in the fourth quarter. Rhumbline Advisers now owns 23,709 shares of the company’s stock valued at $147,000 after acquiring an additional 8,748 shares during the period. Stifel Financial Corp purchased a new position in shares of OptiNose in the fourth quarter valued at about $63,000. Finally, Bank of America Corp DE increased its position in shares of OptiNose by 46.7% in the second quarter. Bank of America Corp DE now owns 34,900 shares of the company’s stock valued at $976,000 after acquiring an additional 11,109 shares during the period. Hedge funds and other institutional investors own 56.96% of the company’s stock.

Shares of NASDAQ OPTN traded up $0.04 during mid-day trading on Thursday, reaching $8.78. 100,843 shares of the company were exchanged, compared to its average volume of 171,182. OptiNose has a 52 week low of $5.66 and a 52 week high of $30.00. The company has a debt-to-equity ratio of 0.61, a quick ratio of 8.01 and a current ratio of 8.28. The company has a market capitalization of $362.26 million, a P/E ratio of -3.28 and a beta of 0.65.

OptiNose (NASDAQ:OPTN) last posted its quarterly earnings data on Wednesday, March 6th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.20. The company had revenue of $3.02 million during the quarter, compared to the consensus estimate of $2.60 million. OptiNose had a negative net margin of 1,509.87% and a negative return on equity of 77.32%. As a group, analysts forecast that OptiNose will post -2.86 EPS for the current fiscal year.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Further Reading: What is the NASDAQ?

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.